ASCO 2022 | CA209-9KY: IMRT + nivolumab for recurrent head and neck squamous cell cancer

Nabil F. Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the CA209-9KY trial (NCT03521570), which investigated the efficacy of intensity-modulated radiotherapy (IMRT) and nivolumab in treating patients with recurrent head and neck squamous cell cancer (HNSCC). After one year, the progression-free survival was 57.8%, and the overall survival was 81.7%. There were also very few severe treatment-related adverse events (AEs), with the most common AEs being fatigue, dermatitis and dysphagia. Hence, IMRT reirradiation with concurrent and adjuvant nivolumab was clinically effective and well-tolerated in patients with HNSCC. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.